Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
It is reported that a genetic polymorphism near the IL28B gene, encoding interferon-λ-3 (IFN-α-2a) is associated with an approximately twofold change in response to treatment, both among patients of European ancestry and African-Americans.
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
It is shown that the C/C genotype strongly enhances resolution of HCV infection among individuals of both European and African ancestry, the strongest and most significant genetic effect associated with natural clearance ofHCV.
Telaprevir for previously untreated chronic hepatitis C virus infection.
Telaprevir with peginterferon-ribavirin was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients.
Sofosbuvir for previously untreated chronic hepatitis C infection.
In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
In patients with chronic hepatitis C, initial therapy withinterferon and ribavirin was more effective than treatment with interferon alone.
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
In patients with HCV genotype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16 weeks of treatment with sofosbuvir and ribvirin was effective.
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
- J. McHutchison, E. Lawitz, M. Sulkowski
- Medicine, BiologyThe New England journal of medicine
- 10 December 2009
In patients infected with HCV genotype 1, the rates of sustained virologic response and tolerability did not differ significantly between theTwo available peginterferon-ribavirin regimens or between the two doses of pegin terferon alfa-2b.
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Once-daily ledipasvir-sofosbuvir with or without ribavirin for 12 or 24 weeks was highly effective in previously untreated patients with HCV genotype 1 infection.